An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

a study on Chronic Kidney Disease Kidney Disease Kidney Transplant Transplants

Summary

Eligibility
for people ages 18-70 (full criteria)
Location
at UC Irvine UCSF
Dates
study started
study ends around
Principal Investigator
by Robert Redfield (uci)

Description

Summary

The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347).

No study drug will be given during this study.

Official Title

A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant

Keywords

Chronic Kidney Disease (CKD), Kidney Transplant, Chronic Renal Insufficiency, Noninterventional, Vonsetamig in study R5459-RT-1944

Eligibility

You can join if…

Open to people ages 18-70

  1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 [NCT05092347].
  2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
  3. Willing and able to comply with clinic visits and study-related procedures
  4. Provide informed consent signed by study patient or legally acceptable representative

You CAN'T join if...

1.There are no exclusion criteria for this study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Locations

  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • Connie Frank Transplant Center at UCSF accepting new patients
    San Francisco California 94143 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States

Lead Scientist at University of California Health

  • Robert Redfield (uci)
    Associate Clinical Professor, Surgery, School of Medicine. Authored (or co-authored) 335 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Regeneron Pharmaceuticals
ID
NCT05106387
Study Type
Observational
Participants
Expecting 20 study participants
Last Updated
Contact us about this trial